EFFER-K 10 MEQ UNFLAVORED- potassium bicarbonate tablet, effervescent EFFER-K 10 MEQ CHERRY VANILLA- potassium bicarbonate tablet, effervescent EFFER-K 20 MEQ UNFLAVORED- potassium bicarbonate tablet, effervescent EFFER-K 20 MEQ ORANGE CREAM- potassium bicarbonate tablet, effervescent
Effer-K by
Drug Labeling and Warnings
Effer-K by is a Prescription medication manufactured, distributed, or labeled by Nomax Inc.. Drug facts, warnings, and ingredients follow.
Drug Details [pdf]
-
Description
Effer-K® 10mEq and 20 mEq Tablets (Effervescent Potassium Bicarbonate/ Citric Acid Tablets for Oral Solution, USP) are intended for the preparation of an oral solution of potassium.
Each 10 mEq tablet contains 1.0g potassium bicarbonate and 0.84g citric acid which, after effervescing, provides a solution containing 10 mEq (391 mg) of elemental potassium as potassium citrate.
Each 20 mEq tablet contains 2.0g potassium bicarbonate and 1.68g citric acid which, after effervescing, provides a solution containing 20 mEq (782 mg) of elemental potassium as potassium citrate.
Tablets also contain maltodextrin, anhydrous dextrose and l-leucine. In addition, the flavored tablets contain SD flavors, and sucralose.
The 10 mEq Cherry Vanilla tablets contain FD&C Red #40 and the 20 mEq Orange Cream tablets contain FD&C Yellow #6 and FD&C Red #40. The Unflavored 10 and 20 mEq tablets do not contain any natural or synthetic dyes, flavors or sweeteners.
The 10 mEq tablets are 11/16 inch diameter round, flat face on both sides with large bevels. EK 10 is imprinted on one side. The 20 mEq tablets are 7/8 inch diameter round, flat face on both sides with large bevels. EK 20 is imprinted on one side. Each tablet is pouched with the product description on one side of the pouch and the lot number, expiration date and bar code on the other
-
Clinical Pharmacology
Potassium ion is the principal intracellular cation of most body tissues, whereas sodium ion is relatively low in concentration. In extracellular fluid the opposite exists, sodium ion being principal and potassium ion being low. The situation is maintained by an active membrane-bound enzyme (Na+K+ATPase). This potassium ion concentration gradient is essential to conduct nerve impulses in such specialized tissues as the brain, heart, and skeletal muscle; and in addition, to maintain normal renal function, acid-base balance, and various cellular metabolic functions. Elimination values are 90% renal and 10% fecal.
Potassium depletion may occur if the rate of potassium ion loss by renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium ion intake. Such depletion usually develops slowly as a consequence of prolonged therapy with oral diuretics, primary or secondary hyperaldosteronism, diabetic ketoacidosis, severe diarrhea, or inadequate replacement of potassium in patients on prolonged parenteral nutrition. Potassium depletion due to these causes is usually accompanied by a concomitant deficiency of chloride and is manifested by hypokalemia and metabolic alkalosis. Potassium depletion may produce weakness, fatigue, mood or mental changes, nausea, vomiting, disturbances of cardiac rhythm (primarily ectopic beats), prominent U-waves in the electrocardiogram, and in advanced cases flaccid paralysis and/or impaired ability to concentrate urine.
-
Indications and Usage
- For therapeutic use in patients with hypokalemia with or without metabolic alkalosis; in chronic digitalis intoxication; and in patients with hypokalemic familial periodic paralysis.
- For prevention of potassium depletion when the dietary intake of potassium ion is inadequate in the following conditions; patients receiving digitalis and diuretics for congestive heart failure; hepatic cirrhosis with ascites; states of aldosterone excess with normal renal function; potassium-losing nephropathy, and certain diarrheal states; long-term corticosteroid therapy.
- The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension or receiving certain antibiotics is often unnecessary when such patients have a normal dietary pattern. Serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases supplementation with potassium salts may be indicated.
-
Contraindications
Potassium supplements are contraindicated in patients with hyperkalemia since a further increase in serum potassium concentration in such patients can produce cardiac arrest. Conditions predisposing to hyperkalemia include: chronic renal failure, acute metabolic acidosis, uncontrolled diabetes mellitus, esophageal compression or delayed gastric emptying or intestinal obstruction/stricture or peptic ulcer. Potassium supplements should be used with caution and only where medically indicated in patients with familial periodic paralysis, myotonia congenita or severe/complete heart block. IMPORTANT: Potassium supplements are contraindicated in patients receiving potassium-sparing diuretics (e.g. spironolactone, triamterene) since such use may produce severe hyperkalemia.
-
Warnings
In patients with hyperkalemia and impaired mechanisms for excreting potassium the administration of potassium salts can produce hyperkalemia and cardiac arrest. This occurs most commonly in patients given potassium by the intravenous route but may also occur in patients given potassium orally. Potentially fatal hyperkalemia can develop rapidly and be asymptomatic.
The use of potassium salts in patients with chronic renal disease, or any other condition which impairs potassium excretion, requires particularly careful monitoring of the serum potassium concentration and appropriate dosage adjustment.
Note: There is no conclusive evidence that potassium supplements lower blood pressure in hypertensive patients.
-
Precautions
The diagnosis of potassium depletion is ordinarily made by demonstrating hypokalemia in a patient with a clinical history suggesting some cause for potassium depletion. In interpreting the serum potassium level, the physician should bear in mind that acute alkalosis per se can produce hypokalemia in the absence of a deficit in total body potassium, while acute acidosis per se can increase the serum potassium concentration into the normal range even in the presence of a reduced total body potassium. The treatment of potassium depletion, particularly in the presence of cardiac disease, renal disease, or acidosis, requires careful attention to acid-base balance and appropriate monitoring of serum electrolytes, the electrocardiogram, and the clinical status of the patient.
Information for patients
To minimize the possibility of gastrointestinal irritation associated with the oral ingestion of concentrated potassium salt preparations, patients should be directed to dissolve each dose completely in the stated amount of water.
Each dose should be taken immediately after a meal or with food. Patients should avoid low-salt foods and salt substitutes, unless approved by physician. The patient should be cautioned to comply strictly with the regimen, particularly when taking diuretics or digitalis, to visit the physician regularly and to report at once any unusual symptoms (e.g. blackish stools, a sign of gastrointestinal bleeding). As with any other medicine, the patient should be counseled on this background information and advised to report to the physician any changes in routine (e.g. starting a fitness program). Proper storage and handling of the product is important. Tablets should not be removed from foil pouch until shortly before use.
Laboratory tests
Frequent clinical evaluation of the patient should include an ECG and a serum potassium level; also, as appropriate, renal function, serum magnesium and serum pH.
Drug Interactions
The simultaneous administration of potassium supplements and a potassium-sparing diuretic can produce severe hyperkalemia (see Contraindications). Potassium supplements should be used cautiously in patients who are using salt substitutes, because most of the latter contain substantial amounts of potassium. Such concomitant use could result in hyperkalemia.
Moreover, the following drugs may produce unfavorable interactions when used concomitantly with potassium supplements: angiotension-converting enzyme (ACE) inhibitors, nonsteroid anti-inflammatory drugs (NSAIDs), beta-adrenergic blocking drugs, heparin, low-salt foods, other potassium containing medications, digitalis glycosides and others.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Potassium is an essential constituent of the human diet. There are no data available on long-term potential for carcinogenicity, mutagenicity, or impairment of fertility in animals or in human beings.
Usage in Pregnancy
Pregnancy Category C
Animal reproduction studies have not been conducted with Effer-K® 10mEq or 20 mEq Tablets (Effervescent Potassium Bicarbonate/ Citric Acid Tablets for Oral Solution, USP). It is also not known whether these products can cause fetal harm when administered to pregnant women or can affect reproduction capacity. Effer-K®10mEq or 20mEq Tablets (Effervescent Potassium Bicarbonate/ Citric Acid Tablets for Oral Solution, USP) should be given to a pregnant woman only if clearly needed.
-
Adverse Reactions
One of the most severe adverse effects is hyperkalemia (see Contraindications, Warnings and Overdosage). The most common adverse reactions to oral potassium salts are nausea, vomiting, abdominal discomfort, and diarrhea. These symptoms are due to irritation of the gastrointestinal tract and are best managed by diluting the preparation further, taking the dose with meals, or reducing the dose. Skin rash has been reported rarely.
-
Overdosage
The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired or if potassium is administered too rapidly intravenously, potentially fatal hyperkalemia can result (see Contraindications and Warnings). It is important to recognize that initally hyperkalemia is usually asymptomatic and may be manifested only by an increased serum potassium concentration and characteristic electrocardiographic changes (peaking of T-waves, loss of P-wave, depression of S-T segment, and prolongation of the QT interval). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest.
Treatment measures for hyperkalemia include the elimination of foods and medications containing potassium and potassium-sparing diuretics, as well as ACE inhibitors, beta blocking agents, NSAIDs, heparin, and cyclosporine. In cases of life-threatening hyperkalemia, treatment measures may include: (1) intravenous administration of 300 to 500 ml/hr of 10% dextrose solution containing 10-20 units of insulin per 1,000 ml; (2) correction of acidosis, if present, with intravenous sodium bicarbonate; (3) use of exchange resins, hemodialysis, or peritoneal dialysis; (4) administration of a calcium salt to antagonize the cardiotoxic effects in patients whose electrocardiograms show appropriate characteristics, and who are not receiving digitalis glycosides; and (5) maintenance of a high urine output in suitable patients.
In treating hyperkalemia, it should be recalled that in patients who have been stabilized on digitalis, rapid lowering of serum potassium can produce digitalis toxicity.
-
Dosage and administration
Effer-K® 10 mEq. Adults - one tablet (Cherry Vanilla or Unflavored) each containing 10 mEq. (391 mg) of elemental potassium, 1 to 4 times daily, depending on the requirement of the patient. Completely dissolve the Cherry Vanilla flavored tablet in 2 to 3 ounces (58 to 85 mL) of cold or ice water before drinking. Completely dissolve the Unflavored tablet in 2 to 3 ounces (58 to 85 mL) of cold juice of choice before drinking.
Effer-K® 20 mEq. Adults - one tablet (Orange Cream or Unflavored) each containing 20 mEq. (782 mg) of elemental potassium, 1 to 4 times daily, depending on the requirement of the patient. Completely dissolve the Orange Cream flavored tablet in 3 to 4 ounces (85 to 115 mL) of cold or ice water before drinking. Completely dissolved the Unflavored tablet in 3 to 4 ounces (85 to 115 mL) of cold juice of choice before drinking.
NOTE: It is suggested that any effervescent potassium tablet be taken with meals and sipped slowly over a 5 to 10 minute period.
-
How Supplied
Each tablet of Effer-K® 10 mEq Tablets (Effervescent Potassium Bicarbonate/ Citric Acid Tablets for Oral Solution, USP) in solution provides 10 mEq (391 mg) of elemental potassium as potassium citrate.
Each tablet of Effer-K® 20 mEq Tablets (Effervescent Potassium Bicarbonate/ Citric Acid Tablets for Oral Solution, USP) in solution provides 20 mEq (782 mg) of elemental potassium as potassium citrate. Store below 40°C (104°F), preferably between 15° and 30°C (59° and 86°F), in original hermetic package.
The 10 mEq tablets are 11/16 inch diameter round, flat face on both sides with large bevels. EK 10 is imprinted on one side of the tablet. Each tablet is pouched with the product description on one side of the pouch and the lot number, expiration date and barcode on the other.
The 20 mEq tablets are 7/8 inch diameter round, flat face on both sides with large bevels. EK 20 is imprinted on one side of the tablet. Each tablet is pouched with the product description on one side of the pouch and the lot number, expiration date and barcode on the other.
NDC: 51801-01330 Unflavored, 10 mEq, package of 30 tablets
NDC: 51801-01430 Cherry Vanilla, 10 mEq, package of 30 tablets
NDC: 51801-01130 Unflavored, 20 mEq, package of 30 tablets
NDC: 51801-01230 Orange Cream, 20 mEq, package of 30 tabletsNomax, Inc. St. Louis, MO 63123 - Made in USA
MSN 015-183Rev. 05/12
-
PRINCIPAL DISPLAY PANEL - 10mEq Tablet Pouch Carton - Unflavored
NDC: 51801-013-30
30 TabletsEffer-K® 10mEq Tablets
POTASSIUM BICARBONATE / CITRIC ACID EFFERVESCENT
TABLETS FOR ORAL SOLUTION, USPUpon effervescing, each tablet provides 10mEq (391mg)
of potassium in solution as potassium citrate.Unflavored
Rx Onlynomax inc
-
PRINCIPAL DISPLAY PANEL - 10 mEq Tablet Pouch Carton - Cherry Vanilla
NDC: 51801-014-30
30 TabletsEffer-K® 10 mEq Tablets
POTASSIUM BICARBONATE / CITRIC ACID EFFERVESCENT
TABLETS FOR ORAL SOLUTION, USPUpon effervescing, each tablet provides 10mEq (391mg)
of potassium in solution as potassium citrate.Cherry Vanilla
Rx Onlynomax inc
-
PRINCIPAL DISPLAY PANEL - 20 mEq Tablet Pouch Carton - Unflavored
NDC: 51801-011-30
30 TabletsEffer-K® 20 mEq Tablets
POTASSIUM BICARBONATE / CITRIC ACID EFFERVESCENT
TABLETS FOR ORAL SOLUTION, USPUpon effervescing, each tablet provides 20mEq (782mg)
of potassium in solution as potassium citrate.Unflavored
Rx Onlynomax inc
-
PRINCIPAL DISPLAY PANEL - 20mEq Tablet Pouch Carton - Orange Cream
NDC: 51801-012-30
30 TabletsEffer-K® 20mEq Tablets
POTASSIUM BICARBONATE / CITRIC ACID EFFERVESCENT
TABLETS FOR ORAL SOLUTION, USPUpon effervescing, each tablet provides 20mEq (782mg)
of potassium in solution as potassium citrate.Orange Cream
Rx Onlynomax inc
-
INGREDIENTS AND APPEARANCE
EFFER-K 10 MEQ UNFLAVORED
potassium bicarbonate tablet, effervescentProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC: 51801-013 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength POTASSIUM BICARBONATE (UNII: HM5Z15LEBN) (POTASSIUM CATION - UNII:295O53K152) POTASSIUM CATION 391 mg Inactive Ingredients Ingredient Name Strength CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP) 840 mg MALTODEXTRIN (UNII: 7CVR7L4A2D) 64.5 mg DEXTROSE (UNII: IY9XDZ35W2) 17.5 mg LEUCINE (UNII: GMW67QNF9C) 45 mg Product Characteristics Color WHITE Score 2 pieces Shape ROUND Size 17mm Flavor Imprint Code EK;10 Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC: 51801-013-30 30 in 1 CARTON 01/30/2013 1 1 in 1 POUCH; Type 0: Not a Combination Product Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date UNAPPROVED DRUG OTHER 01/30/2013 EFFER-K 10 MEQ CHERRY VANILLA
potassium bicarbonate tablet, effervescentProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC: 51801-014 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength POTASSIUM BICARBONATE (UNII: HM5Z15LEBN) (POTASSIUM CATION - UNII:295O53K152) POTASSIUM CATION 391 mg Inactive Ingredients Ingredient Name Strength CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP) 840 mg MALTODEXTRIN (UNII: 7CVR7L4A2D) 17.5 mg DEXTROSE (UNII: IY9XDZ35W2) 17.5 mg LEUCINE (UNII: GMW67QNF9C) 45 mg Product Characteristics Color PINK Score 2 pieces Shape ROUND Size 17mm Flavor CHERRY (Cherry Vanilla) Imprint Code EK;10 Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC: 51801-014-30 30 in 1 CARTON 01/30/2013 1 1 in 1 POUCH; Type 0: Not a Combination Product Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date UNAPPROVED DRUG OTHER 01/30/2013 EFFER-K 20 MEQ UNFLAVORED
potassium bicarbonate tablet, effervescentProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC: 51801-011 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength POTASSIUM BICARBONATE (UNII: HM5Z15LEBN) (POTASSIUM CATION - UNII:295O53K152) POTASSIUM CATION 782 mg Inactive Ingredients Ingredient Name Strength CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP) 1680 mg MALTODEXTRIN (UNII: 7CVR7L4A2D) 129 mg DEXTROSE (UNII: IY9XDZ35W2) 35 mg LEUCINE (UNII: GMW67QNF9C) 90 mg Product Characteristics Color WHITE Score 2 pieces Shape ROUND Size 22mm Flavor Imprint Code EK;20 Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC: 51801-011-30 30 in 1 CARTON 01/30/2013 1 1 in 1 POUCH; Type 0: Not a Combination Product Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date UNAPPROVED DRUG OTHER 01/30/2013 EFFER-K 20 MEQ ORANGE CREAM
potassium bicarbonate tablet, effervescentProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC: 51801-012 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength POTASSIUM BICARBONATE (UNII: HM5Z15LEBN) (POTASSIUM CATION - UNII:295O53K152) POTASSIUM CATION 782 mg Inactive Ingredients Ingredient Name Strength CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP) 1680 mg MALTODEXTRIN (UNII: 7CVR7L4A2D) 35 mg DEXTROSE (UNII: IY9XDZ35W2) 35 mg LEUCINE (UNII: GMW67QNF9C) 90 mg Product Characteristics Color ORANGE Score 2 pieces Shape ROUND Size 22mm Flavor ORANGE (Orange Cream) Imprint Code EK;20 Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC: 51801-012-30 30 in 1 CARTON 01/30/2013 1 1 in 1 POUCH; Type 0: Not a Combination Product Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date UNAPPROVED DRUG OTHER 01/30/2013 Labeler - Nomax Inc. (103220273) Establishment Name Address ID/FEI Business Operations Nomax Inc. 103220273 MANUFACTURE(51801-013, 51801-014, 51801-011, 51801-012)
Trademark Results [Effer-K]
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 EFFER-K 73402235 1295554 Live/Registered |
Nomax, Inc. 1982-11-10 |
© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.